%0 Journal Article
%A Akbaba, Sati
%A Rühle, Alexander
%A Rothhaar, Sofie
%A Zamboglou, Constantinos
%A Gkika, Eleni
%A Foerster, Robert
%A Oebel, Laura
%A Klodt, Tristan
%A Schmidberger, Heinz
%A Grosu, Anca-Ligia
%A Debus, Jürgen
%A Bostel, Tilman
%A Nicolay, Nils H
%T Treatment outcomes of elderly salivary gland cancer patients undergoing radiotherapy - results from a large multicenter analysis.
%J Radiotherapy and oncology
%V 156
%@ 0167-8140
%C Amsterdam [u.a.]
%I Elsevier Science
%M DKFZ-2020-03050
%P 266-274
%D 2021
%Z Volume 156, March 2021, Pages 266-274 / #LA:E055#
%X To evaluate oncological outcomes and treatment-related toxicities of elderly salivary gland cancer patients undergoing (chemo)radiotherapy.Local/locoregional control (LRC), progression-free survival (PFS) and overall survival (OS) of elderly patients ≥65 years with primary salivary gland cancers undergoing (chemo)radiotherapy between 2005 and 2020 at three tertiary cancer centers were calculated. The impact of clinicopathological and treatment parameters on outcomes were analyzed, and acute and chronic toxicities were quantified.288 elderly salivary gland cancer patients were included in this multicenter analysis, and their median LRC, PFS and OS amounted to 113, 39 and 75 months, respectively. Age, performance status, comorbidities, definitive vs. adjuvant (chemo)radiotherapy as well as locally/locoregionally advanced cancers and distant metastases correlated with reduced outcomes in elderly salivary gland patients. Patients receiving dose-escalated radiotherapy (total doses >70 GyEQD2) with carbon ion boost radiation resulted in improved LRC, but no improvements in PFS or OS. Concomitant chemoradiotherapy did not improve treatment outcomes in elderly salivary gland carcinoma patients. Radiotherapy of elderly salivary gland cancer patients resulted in moderate higher-grade toxicities despite dose escalation with 70 (24.3
%K Chemotherapy (Other)
%K Elderly patients (Other)
%K Geriatric patients (Other)
%K Head-and-neck cancer (Other)
%K Radiotherapy (Other)
%K Salivary gland cancer (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:33359662
%R 10.1016/j.radonc.2020.12.024
%U https://inrepo02.dkfz.de/record/166614